John P. Saharek
2016
In 2016, John P. Saharek earned a total compensation of $550.9K as Chief Commercial Officer at Imprimis Pharmaceuticals, a 47% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $102,596 |
|---|---|
| Option Awards | $192,420 |
| Salary | $247,288 |
| Other | $8,576 |
| Total | $550,880 |
Saharek received $247.3K in salary, accounting for 45% of the total pay in 2016.
Saharek also received $102.6K in non-equity incentive plan, $192.4K in option awards and $8.6K in other compensation.
Rankings
In 2016, John P. Saharek's compensation ranked 10,833rd out of 14,075 executives tracked by ExecPay. In other words, Saharek earned more than 23.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,833 out of 14,075 | 23rd |
Division Manufacturing | 4,212 out of 5,486 | 23rd |
Major group Chemicals And Allied Products | 1,503 out of 1,900 | 21st |
Industry group Drugs | 1,209 out of 1,543 | 22nd |
Industry Pharmaceutical Preparations | 942 out of 1,173 | 20th |
Source: SEC filing on April 27, 2017.
Saharek's colleagues
We found two more compensation records of executives who worked with John P. Saharek at Imprimis Pharmaceuticals in 2016.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019